TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Sponsor: Dana-Farber Cancer Institute · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,524,600

Rescue Site Savings

+$1,016,400

Unlock Full NCT04434040 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04434040 Rescue Dossier →